Jong K Yun

Dr. Jong K Yun

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2008 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
RZRanran Zhang
Ranran Zhang
MSMithun Vinod Shah
Mithun Vinod Shah
JYJun Yang
Jun Yang
SNSusan B. Nyland
Susan B. Nyland
XLXin Liu
Xin Liu
TLThomas P. Loughran
Thomas P. Loughran
T cell large granular lymphocyte (T-LGL) leukemia features a clonal expansion of antigen-primed, competent, cytotoxic T lymphocytes (CTL). To systematically understand signaling components that determine the survival of CTL in T-LGL leukemia, we constructed a T-LGL survival signaling network by integrating the signaling pathways involved in normal CTL activation and the known deregulations of survival signaling in leukemic T-LGL. This network was subsequently translated into a predictive, discrete, dynamic model. Our model suggests that the persistence of IL-15 and PDGF is sufficient to reproduce all known deregulations in leukemic T-LGL. This finding leads to the following predictions: ( i ) Inhibiting PDGF signaling induces apoptosis in leukemic T-LGL. ( ii ) Sphingosine kinase 1 and NFκB are essential for the long-term survival of CTL in T-LGL leukemia. ( iii ) NFκB functions downstream of PI3K and prevents apoptosis through maintaining the expression of myeloid cell leukemia sequence 1. ( iv ) T box expressed in T cells (T-bet) should be constitutively activated concurrently with NFκB activation to reproduce the leukemic T-LGL phenotype. We validated these predictions experimentally. Our study provides a model describing the signaling network involved in maintaining the long-term survival of competent CTL in humans. The model will be useful in identifying potential therapeutic targets for T-LGL leukemia and generating long-term competent CTL necessary for tumor and cancer vaccine development.

1 April 2012 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
MYMegan M. Young
Megan M. Young
YTYoshinori Takahashi
Yoshinori Takahashi
OKOsman Khan
Osman Khan
SPSungman Park
Sungman Park
THTsukasa Hori
Tsukasa Hori
Hong-Gang WangHong-Gang Wang
Hong-Gang Wang
Autophagy and apoptosis are two evolutionarily conserved processes that regulate cell fate in response to cytotoxic stress. However, the functional relationship between these two processes remains far from clear. Here, we demonstrate an autophagy-dependent mechanism of caspase-8 activation and initiation of the apoptotic cascade in response to SKI-I, a pan-sphingosine kinase inhibitor, and bortezomib, a proteasome inhibitor. Autophagy is induced concomitantly with caspase-8 activation, which is responsible for initiation of the caspase cascade and the mitochondrial amplification loop that is required for full execution of apoptosis. Inhibition of autophagosome formation by depletion of Atg5 or Atg3 results in a marked suppression of caspase-8 activation and apoptosis. Although caspase-8 self-association depends on p62/SQSTM1, its self-processing requires the autophagosomal membrane. Caspase-8 forms a complex with Atg5 and colocalizes with LC3 and p62. Moreover, FADD, an adaptor protein for caspase-8 activation, associates with Atg5 on Atg16L- and LC3-positive autophagosomal membranes and loss of FADD suppresses cell death. Taken together, these results indicate that the autophagosomal membrane serves as a platform for an intracellular death-inducing signaling complex (iDISC) that recruits self-associated caspase-8 to initiate the caspase-8/-3 cascade.

30 October 2008 in Nano Letters
Verified
Journal Article
Closed access
TMThomas T. Morgan
Thomas T. Morgan
HMHari S. Muddana
Hari S. Muddana
EAErhan İ. Altinoǧlu
Erhan İ. Altinoǧlu
SRSarah M. Rouse
Sarah M. Rouse
ATAmra Tabaković
Amra Tabaković
JAJames Hansell Adair
James Hansell Adair

15 September 2003
Verified
Journal Article
Closed access
KFKevin J French
Kevin J French
RSRandy S Schrecengost
Randy S Schrecengost
BLBrian D Lee
Brian D Lee
YZYan Zhuang
Yan Zhuang
SSStaci N Smith
Staci N Smith
CSCharles D Smith
Charles D Smith

1 November 2000 in Journal of Biological Chemistry
Verified
Journal Article
Open access
NBNicole A. Bourbon
Nicole A. Bourbon
JYJong K Yun
Jong K Yun
MKMark Kester
Mark Kester
We have previously shown that interleukin 1 (IL-1)-receptor-generated ceramide induces growth arrest in smooth muscle pericytes by activating an upstream kinase in the stress-activated protein kinase (SAPK) cascade. We now report the mechanism by which ceramide activates the SAPK signaling pathway in human embryonic kidney cells (HEK-293). We demonstrate that ceramide activation of protein kinase C zeta (PKCzeta) mediates SAPK signal complex formation and subsequent growth suppression. Ceramide directly activates both immunoprecipitated and recombinant human PKCzeta in vitro. Additionally, ceramide activates SAPK activity, which is blocked with a dominant-negative mutant of PKCzeta. Co-immunoprecipitation studies reveal that ceramide induces the association of SAPK with PKCzeta, but not with PKCepsilon. In addition, ceramide treatment induces PKCzeta association with phosphorylated SEK and MEKK1, elements of the SAPK signaling complex. The biological role of ceramide to induce cell cycle arrest is mimicked by overexpression of a constitutively active PKCzeta. Together, these studies demonstrate that ceramide induces cell cycle arrest by enhancing the ability of PKCzeta to form a signaling complex with MEKK1, SEK, and SAPK.

1 August 2006 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
KFKevin J. French
Kevin J. French
JUJohn J. Upson
John J. Upson
SKStaci N. Keller
Staci N. Keller
YZYan Zhuang
Yan Zhuang
JYJong K Yun
Jong K Yun
CSCharles D. Smith
Charles D. Smith
Sphingosine kinase (SK) is an oncogenic sphingolipid-metabolizing enzyme that catalyzes the formation of the mitogenic second messenger sphingosine-1-phosphate (S1P) at the expense of proapoptotic ceramide. Thus, SK is an attractive target for cancer therapy because blockage of S1P formation leads to inhibition of proliferation, as well as the induction of apoptosis in cancer cells. We have recently identified novel SK inhibitors with nanomolar to low micromolar potencies toward recombinant human SK. This study describes the continuing analysis of these inhibitors through in vitro and in vivo experiments. All three structurally diverse SK inhibitors tested showed antitumor activity in mice without exhibiting toxicity. Blood and tumor inhibitor concentrations exceeded in vitro potency levels. Cell signaling analyses in vitro revealed mixed inhibition of mitogen-activated protein kinase kinase and Akt phosphorylation by the SK inhibitors. Importantly, 4-[4-(4-chloro-phenyl)-thiazol-2-ylamino]-phenol (SKI-II) is orally bioavailable, detected in the blood for at least 8 h, and showed a significant inhibition of tumor growth in mice. These compounds are the first examples of nonlipid selective inhibitors of SK with in vivo antitumor activity and provide leads for further development of inhibitors of this important molecular target.